Sofina India

Sofina is a Brussels-based, family-backed global investment firm with a long-duration capital base, deploying Series B, Series C, and growth-stage checks of $25M and up. The Sofina India franchise is the firm’s lens into Indian growth-stage companies, particularly in healthcare and digital transformation, where it has historically taken concentrated positions in market-leading platforms and held them across multiple rounds. The right founder is a CEO of an Indian healthcare or digital company with strong unit economics, a defensible market position, and a path to either a public listing or strategic exit at scale. Sofina is not a fund for early-stage bets, AI-first software at Seed, or capital-light experiments; it underwrites structural winners. Healthcare relevance includes major care delivery platforms, large diagnostic networks, pharma and therapeutics companies with branded portfolios, and tech-enabled services with proven scale. Founders raising less than $25M, pre-Series B, or with sub-scale revenue should look elsewhere. Geographic and structural advantage is the patient capital posture. Sofina’s family backing means it does not need to chase quarterly liquidity, can support holds beyond seven or eight years when the business warrants, and is a credible partner for founders who genuinely want to build a generational company. That capital patience is rare and meaningful. The flip side is rigorous diligence: governance, ESG, data integrity, and clinical safety review are deeper than typical growth investors apply. Best entry path is via established Indian growth-stage banker relationships, the major Indian VC and PE syndicates that have co-invested with Sofina, or direct outreach when revenue and audited financials are at the level the firm takes seriously. The Sofina India team is small and selective; cold-pitch volume is low and conversion correlates with reference quality. Lead the pitch with audited financials, cohort and unit economics, governance maturity, and a clean answer on how the IPO or strategic exit pathway works in your market. Be explicit about regulator relationships, clinical quality systems, and any material litigation or compliance history. Caveats: Sofina takes large stakes and expects board-level engagement, so founders should be ready for an active partner. Negotiate governance and information rights carefully, because long-hold capital correlates with strong reporting expectations. Ask the team directly about how follow-on is handled in down cycles and how secondary liquidity for early shareholders is structured. Used appropriately, Sofina is one of the more credible long-term growth partners available to Indian healthcare CEOs.